|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.96 USD | -0.94% |
|
-2.41% | -0.58% |
| 04-09 | BridgeBio Pharma Evolving Into Rare Disease Powerhouse From TTR Roots, RBC Says | MT |
| 04-09 | RBC Initiates BridgeBio Pharma at Outperform, Speculative Risk With $100 Price Target | MT |
| Capitalization | 14.87B 12.65B 11.6B 11.01B 20.29B 1,391B 20.74B 136B 53.61B 667B 55.76B 54.61B 2,370B | P/E ratio 2026 * |
-39.3x | P/E ratio 2027 * | 118x |
|---|---|---|---|---|---|
| Enterprise value | 16.19B 13.78B 12.64B 11.99B 22.1B 1,515B 22.59B 148B 58.4B 727B 60.74B 59.49B 2,582B | EV / Sales 2026 * |
17.7x | EV / Sales 2027 * | 9.9x |
| Free-Float |
78.66% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BridgeBio Pharma, Inc.
| 1 day | -0.98% | ||
| 1 week | -2.41% | ||
| Current month | +2.41% | ||
| 1 month | +9.27% | ||
| 3 months | -2.69% | ||
| 6 months | +39.90% | ||
| Current year | -0.58% |
| 1 week | 74.94 |  | 79.62 |
| 1 month | 67.57 | | 79.62 |
| Current year | 62.77 | | 84.94 |
| 1 year | 31.77 | | 84.94 |
| 3 years | 12.75 | | 84.94 |
| 5 years | 4.98 | | 84.94 |
| 10 years | 4.98 | | 84.94 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Corporate Officer/Principal | 75 | 31/03/2019 | |
Neil Kumar
CEO | Chief Executive Officer | 47 | 31/03/2015 |
Charles Homcy
PRN | Corporate Officer/Principal | 77 | 31/01/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Ronald Daniels
BRD | Director/Board Member | 66 | 11/02/2020 |
James Momtazee
BRD | Director/Board Member | 54 | 29/02/2016 |
| Director/Board Member | 75 | 20/02/2023 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.94% | -2.41% | +126.95% | +378.90% | 14.87B | |
| -0.61% | -1.32% | +32.78% | -6.89% | 76.9B | |
| -4.59% | -8.68% | +76.25% | +181.76% | 58.1B | |
| -1.06% | +58.80% | +58.80% | +58.80% | 50.55B | |
| -0.31% | -0.21% | -42.76% | -54.31% | 47.27B | |
| +1.78% | +4.45% | +60.47% | -36.42% | 26.91B | |
| +0.31% | +3.45% | +117.53% | -61.19% | 21.65B | |
| -0.26% | -0.88% | +70.48% | +29.82% | 19.29B | |
| -1.48% | +0.19% | +55.16% | +54.81% | 15.83B | |
| -0.67% | +4.38% | -6.11% | +688.46% | 13.53B | |
| Average | -0.78% | +0.66% | +54.95% | +123.37% | 34.49B | |
| Weighted average by Cap. | -1.10% | -0.14% | +46.71% | +71.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 913M 777M 713M 676M 1.25B 85.43B 1.27B 8.37B 3.29B 40.99B 3.43B 3.35B 146B | 1.58B 1.35B 1.23B 1.17B 2.16B 148B 2.21B 14.5B 5.71B 71.02B 5.93B 5.81B 252B |
| Net income | -377M -321M -294M -279M -514M -35.26B -526M -3.45B -1.36B -16.92B -1.41B -1.38B -60.08B | 124M 106M 96.89M 91.92M 169M 11.62B 173M 1.14B 448M 5.57B 466M 456M 19.79B |
| Net Debt | 1.33B 1.13B 1.04B 983M 1.81B 124B 1.85B 12.17B 4.79B 59.62B 4.98B 4.88B 212B | 801M 681M 625M 593M 1.09B 74.91B 1.12B 7.34B 2.89B 35.94B 3B 2.94B 128B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/04/26 | 76.05 $ | -0.82% | 575,795 |
| 20/04/26 | 76.68 $ | -0.09% | 1,650,451 |
| 17/04/26 | 76.75 $ | -0.98% | 2,044,814 |
| 16/04/26 | 77.51 $ | -0.24% | 917,778 |
| 15/04/26 | 77.70 $ | -0.30% | 1,562,921 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BBIO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition